@nejm.org
Every post by NEJM.org we've fact-checked.
Among patients with multiple myeloma, 7-year overall survival with 2 years of lenalidomide therapy was similar to that with indefinite therapy. Adverse events and second cancers were more common with indefinite therapy. Full phase 3 ENDURANCE trial results: https://nej.md/3TlfOlb
